Fortress Biotech Inc 주요 수익원은 Journey이며, 최신 수익 발표에서 수익은 61,858,000입니다. 지역별로는 United States이 Fortress Biotech Inc의 주요 시장이며, 수익은 63,262,000입니다.
Fortress Biotech Inc은 수익성이 있나요?
no, 최신 재무제표에 따르면 Fortress Biotech Inc의 순손실은 $0입니다.
Fortress Biotech Inc에 부채가 있나요?
no, Fortress Biotech Inc의 부채는 0입니다.
Fortress Biotech Inc의 발행 주식은 몇 주인가요?
Fortress Biotech Inc의 총 발행 주식은 0주입니다.
주요 통계
이전 종가
$14.02
시가
$14
일일 범위
$13.85 - $15.49
52주 범위
$1.6 - $15.01
거래량
71.0K
평균 거래량
797.2K
배당수익률
0.91%
EPS(TTM)
0.17
시가총액
$483.3M
FBIOP란 무엇인가요?
Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. The company is headquartered in Bay Harbor Islands, Florida and currently employs 78 full-time employees. The company went IPO on 2011-11-17. The firm has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13Rα2 CAR T Cell Program for Glioblastoma), and others.